International Stem Cell (OTCMKTS:ISCO – Get Free Report) posted its quarterly earnings results on Friday. The biotechnology company reported ($0.11) earnings per share for the quarter, Zacks reports.
International Stem Cell Stock Performance
ISCO remained flat at $0.17 during trading hours on Friday. The company had a trading volume of 23,252 shares, compared to its average volume of 18,829. The stock has a market cap of $1.38 million, a PE ratio of -2.11 and a beta of 0.08. International Stem Cell has a 12-month low of $0.12 and a 12-month high of $0.54. The business has a fifty day moving average of $0.24 and a 200-day moving average of $0.22.
International Stem Cell Company Profile
International Stem Cell Corporation is a biotechnology company focused on developing products and therapies using its proprietary human parthenogenetic stem cell technology. These cells are created from unfertilized human eggs and have been studied for their potential use in regenerative medicine. The company has pursued stem cell-based programs for neurological conditions, including Parkinson’s disease, and has developed stem cell-derived ingredients for skin-care products sold through its Lifeline Skin Care business.
Read More
- Five stocks we like better than International Stem Cell
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
